688176 亚虹医药-U
交易中 08-26 14:04:39
资讯
新帖
简况
每周股票复盘：亚虹医药（688176）APL-2501获FDA临床试验批准
证券之星 · 08-16
每周股票复盘：亚虹医药（688176）APL-2501获FDA临床试验批准
亚虹医药（688176）披露APL-2501临床试验申请获得FDA批准，8月13日股价上涨3.29%
证券之星 · 08-13
亚虹医药（688176）披露APL-2501临床试验申请获得FDA批准，8月13日股价上涨3.29%
每周股票复盘：亚虹医药（688176）就Photocure仲裁案提起反请求
证券之星 · 08-09
每周股票复盘：亚虹医药（688176）就Photocure仲裁案提起反请求
亚虹医药（688176）披露关于仲裁进展暨提起仲裁反请求的公告，8月5日股价上涨6.8%
证券之星 · 08-05
亚虹医药（688176）披露关于仲裁进展暨提起仲裁反请求的公告，8月5日股价上涨6.8%
每周股票复盘：亚虹医药（688176）收仲裁通知涉440万美元
证券之星 · 07-26
每周股票复盘：亚虹医药（688176）收仲裁通知涉440万美元
亚虹医药（688176）披露关于收到仲裁通知的公告，7月23日股价上涨1.14%
证券之星 · 07-23
亚虹医药（688176）披露关于收到仲裁通知的公告，7月23日股价上涨1.14%
亚虹医药（688176）1.35亿股限售股将于7月1日解禁，占总股本23.68%
证券之星 · 07-01
亚虹医药（688176）1.35亿股限售股将于7月1日解禁，占总股本23.68%
每周股票复盘：亚虹医药（688176）23.68%限售股将上市流通
证券之星 · 06-28
每周股票复盘：亚虹医药（688176）23.68%限售股将上市流通
亚虹医药（688176）披露首次公开发行部分限售股上市流通公告，6月23日股价上涨0.5%
证券之星 · 06-23
亚虹医药（688176）披露首次公开发行部分限售股上市流通公告，6月23日股价上涨0.5%
每周股票复盘：亚虹医药（688176）两期股权激励完成归属
证券之星 · 06-20
每周股票复盘：亚虹医药（688176）两期股权激励完成归属
亚虹医药（688176）披露核心技术人员调整公告，6月17日股价下跌2.22%
证券之星 · 06-17
亚虹医药（688176）披露核心技术人员调整公告，6月17日股价下跌2.22%
亚虹医药（688176）披露2024年限制性股票激励计划第一个归属期归属结果公告，6月16日股价上涨1.57%
证券之星 · 06-16
亚虹医药（688176）披露2024年限制性股票激励计划第一个归属期归属结果公告，6月16日股价上涨1.57%
每周股票复盘：亚虹医药（688176）2025年股东会通过利润分配等议案
证券之星 · 05-31
每周股票复盘：亚虹医药（688176）2025年股东会通过利润分配等议案
亚虹医药（688176）披露2025年年度股东会法律意见书，5月27日股价下跌2.43%
证券之星 · 05-27
亚虹医药（688176）披露2025年年度股东会法律意见书，5月27日股价下跌2.43%
每周股票复盘：亚虹医药（688176）核心产品获批推进商业化布局
证券之星 · 05-24
每周股票复盘：亚虹医药（688176）核心产品获批推进商业化布局
亚虹医药（688176）披露证券事务代表辞职公告，5月22日股价上涨0.32%
证券之星 · 05-22
亚虹医药（688176）披露证券事务代表辞职公告，5月22日股价上涨0.32%
亚虹医药（688176）披露2025年年度股东会会议资料，5月20日股价下跌0.32%
证券之星 · 05-20
亚虹医药（688176）披露2025年年度股东会会议资料，5月20日股价下跌0.32%
每周股票复盘：亚虹医药（688176）希维她商业化推进及海外临床进展
证券之星 · 05-17
每周股票复盘：亚虹医药（688176）希维她商业化推进及海外临床进展
股市必读：亚虹医药（688176）5月11日披露最新机构调研信息
证券之星 · 05-12
股市必读：亚虹医药（688176）5月11日披露最新机构调研信息
亚虹医药：5月11日召开业绩说明会
证券之星 · 05-11
亚虹医药：5月11日召开业绩说明会
公司概况
公司名称：
江苏亚虹医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-07
主营业务：
江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域专科创新药的研发、生产和销售。公司的主要产品是APL-1702(希维她)、APL-2302、APL-2501、AT-018、AT-021、APL-1706(海克威)、APLD-2304、APL-1202、APL-2401、APL-1202、APL-1401、APL-2301。
发行价格：
22.98
{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药-U","latestPrice":11.73,"timestamp":1787724279000,"preClose":11.82,"halted":0,"volume":7193660,"delay":0,"changeRate":-0.0076,"floatShares":572000000,"shares":572000000,"eps":-0.7782,"marketStatus":"交易中","change":-0.09,"latestTime":"08-26 14:04:39","open":11.79,"high":12.09,"low":11.66,"amount":85216700,"amplitude":0.0364,"askPrice":11.74,"askSize":22,"bidPrice":11.73,"bidSize":30,"shortable":0,"etf":0,"ttmEps":-0.7782,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787727600000},"marketStatusCode":2,"adr":0,"adjPreClose":11.82,"symbolType":"stock_kcb","openAndCloseTimeList":[[1787707800000,1787715000000],[1787720400000,1787727600000]],"highLimit":13,"lowLimit":10.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":572192168,"isCdr":false,"pbRate":4.61,"roa":"--","roe":"--","epsLYR":-0.74,"committee":0.437593,"marketValue":6712000000,"turnoverRate":0.0126,"status":1,"floatMarketCap":6712000000},"requestUrl":"/m/hq/s/688176/wiki","defaultTab":"wiki","newsList":[{"id":"2659176955","title":"每周股票复盘：亚虹医药（688176）APL-2501获FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176955","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176955?lang=zh_cn&edition=full","pubTime":"2026-08-16 03:10","pubTimestamp":1786821019,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，亚虹医药报收于12.98元，较上周的12.81元上涨1.33%。本周，亚虹医药8月13日盘中最高价报13.65元。本周关注点公司公告汇总：APL-2501获FDA同意开展晚期实体瘤临床试验公司公告汇总江苏亚虹医药科技股份有限公司控股子公司Baylink Biosciences Inc收到美国食品药品监督管理局函告，同意其自主研发的APL-2501开展用于治疗晚期实体瘤的临床试验。APL-2501是一种抗CLDN6/9抗体药物偶联物，拟用于多种晚期实体瘤治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","BK0239","BK1515","688176","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659391163","title":"亚虹医药（688176）披露APL-2501临床试验申请获得FDA批准，8月13日股价上涨3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659391163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659391163?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:31","pubTimestamp":1786631471,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，亚虹医药报收于13.2元，较前一交易日上涨3.29%，最新总市值为75.53亿元。近日，江苏亚虹医药科技股份有限公司控股子公司Baylink Biosciences Inc收到美国食品药品监督管理局函告，同意其自主研发的APL-2501开展用于治疗晚期实体瘤的临床试验。APL-2501是一种抗CLDN6/9抗体药物偶联物，拟用于多种晚期实体瘤治疗。该临床试验申请获批对公司近期业绩无重大影响，药品研发仍存在技术、审批等不确定性风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","09939","BK1161","BK0239","688176","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658200673","title":"每周股票复盘：亚虹医药（688176）就Photocure仲裁案提起反请求","url":"https://stock-news.laohu8.com/highlight/detail?id=2658200673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658200673?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:00","pubTimestamp":1786212048,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，亚虹医药报收于12.81元，较上周的11.36元上涨12.76%。本周，亚虹医药8月7日盘中最高价报12.87元。本周关注点公司公告汇总：亚虹医药及子公司就Photocure仲裁案提起反请求，要求返还660万美元及利息。此前，Photocure因合同纠纷于2026年7月提起仲裁，主张公司未支付全额里程碑款项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1574","09939","BK0239","BK1161","159938","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657722528","title":"亚虹医药（688176）披露关于仲裁进展暨提起仲裁反请求的公告，8月5日股价上涨6.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657722528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657722528?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:12","pubTimestamp":1785939141,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，亚虹医药报收于12.4元，较前一交易日上涨6.8%，最新总市值为70.95亿元。该股当日开盘11.64元，最高12.49元，最低11.62元，成交额达2.29亿元，换手率为3.29%。近日，江苏亚虹医药科技股份有限公司发布《关于仲裁进展暨提起仲裁反请求的公告》。此前，Photocure因合同纠纷于2026年7月提起仲裁，主张公司未支付全额里程碑款项。公司表示已依约支付相关款项并保留权利，反请求已获受理，但尚未开庭审理，最终影响以仲裁结果为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","09939","688176","BK0239","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052771","title":"每周股票复盘：亚虹医药（688176）收仲裁通知涉440万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052771?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:58","pubTimestamp":1785002293,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，亚虹医药报收于12.58元，较上周的13.03元下跌3.45%。本周，亚虹医药7月22日盘中最高价报14.51元。Photocure请求裁定公司支付剩余440万美元及利息，并承担仲裁费用。目前仲裁已受理，尚未开庭。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","09939","159938","BK1161","BK1574","BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653295107","title":"亚虹医药（688176）披露关于收到仲裁通知的公告，7月23日股价上涨1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653295107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653295107?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:35","pubTimestamp":1784817317,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，亚虹医药报收于13.25元，较前一交易日上涨1.14%，最新总市值为75.82亿元。Photocure主张公司应支付因希维她获批而触发的1,100万美元里程碑款，公司已于2026年4月支付660万美元并保留权利，认为未触发全额付款义务。Photocure请求裁定公司支付剩余440万美元及利息，并承担仲裁费用。目前仲裁已受理，尚未开庭。该事项未对公司与Photocure的长期合作及正常经营造成实质性障碍，希维她的生产供应与商业化正有序推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300048226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159938","BK1574","09939","688176","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648459390","title":"亚虹医药（688176）1.35亿股限售股将于7月1日解禁，占总股本23.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648459390","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648459390?lang=zh_cn&edition=full","pubTime":"2026-07-01 08:03","pubTimestamp":1782864190,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，亚虹医药于7月1日将有1.35亿股限售股份解禁，为公司追加承诺限售股份上市流通，占公司总股本23.68%。最近一年内，该股累计解禁5623.45万股，占总股本的9.83%。本文数据来源于亚虹医药公告，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100009448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","BK1574","BK1161","BK1515","BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646031302","title":"每周股票复盘：亚虹医药（688176）23.68%限售股将上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2646031302","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646031302?lang=zh_cn&edition=full","pubTime":"2026-06-28 02:57","pubTimestamp":1782586627,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，亚虹医药报收于9.19元，较上周的10.18元下跌9.72%。本周，亚虹医药6月23日盘中最高价报10.31元。6月26日盘中最低价报9.17元。亚虹医药当前最新总市值52.58亿元，在化学制药板块市值排名81/150，在两市A股市值排名3029/5206。涉及股东为PAN KE和ZHUANG CHENGFENG JOHN，分别持有129,465,348股和6,019,189股，解除限售后剩余限售股数量为0。上述股份锁定期为公司上市之日起三个完整会计年度后6个月，相关股东已严格履行限售承诺，保荐机构中信证券无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1161","688176","BK0239","159938","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645832975","title":"亚虹医药（688176）披露首次公开发行部分限售股上市流通公告，6月23日股价上涨0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645832975","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645832975?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:22","pubTimestamp":1782224535,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，亚虹医药报收于10.04元，较前一交易日上涨0.5%，最新总市值为57.45亿元。近日，江苏亚虹医药科技股份有限公司发布首次公开发行部分限售股上市流通公告。公告显示，本次解除限售股份数量为135,484,537股，占公司当前总股本的23.68%。本次限售股将于2026年7月1日上市流通，涉及股东2名，分别为PAN KE和ZHUANG CHENGFENG JOHN；解除限售后剩余限售股数量为0。上述股东均严格履行了限售承诺，保荐机构中信证券对本次限售股上市流通无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK1161","159938","BK0239","09939","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644632860","title":"每周股票复盘：亚虹医药（688176）两期股权激励完成归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2644632860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644632860?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:19","pubTimestamp":1781893150,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，亚虹医药报收于10.18元，较上周的10.3元下跌1.17%。本周关注点公司公告汇总：2024年限制性股票激励计划首个归属期完成，归属2,551,416股。江苏亚虹医药科技股份有限公司完成2022年限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。实际归属人数为73名，其中首次授予部分68人，归属923,932股；预留授予部分5人，归属97,750股。本次归属后公司总股本增至572,192,168股，未导致控股股东及实际控制人变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK0239","688176","BK1574","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644742435","title":"亚虹医药（688176）披露核心技术人员调整公告，6月17日股价下跌2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644742435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644742435?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:53","pubTimestamp":1781707990,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，亚虹医药报收于10.15元，较前一交易日下跌2.22%，最新总市值为58.08亿元。该股当日开盘10.3元，最高10.38元，最低10.1元，成交额达5654.03万元，换手率为1.27%。近日，江苏亚虹医药科技股份有限公司发布《关于调整核心技术人员的公告》。公告显示，公司新认定Ningshu Liu女士、马集先生为公司核心技术人员；原核心技术人员吴亮、孙龙伟不再认定为核心技术人员，但仍继续在公司任职。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643763494","title":"亚虹医药（688176）披露2024年限制性股票激励计划第一个归属期归属结果公告，6月16日股价上涨1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643763494","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643763494?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:32","pubTimestamp":1781620335,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，亚虹医药报收于10.38元，较前一交易日上涨1.57%，最新总市值为59.29亿元。该股当日开盘10.22元，最高10.49元，最低10.07元，成交额达8857.87万元，换手率为1.98%。近日，江苏亚虹医药科技股份有限公司发布《关于2024年限制性股票激励计划第一个归属期归属结果公告》。公告显示，公司已完成2024年限制性股票激励计划第一个归属期的股份登记，本次归属股票数量为2,551,416股，来源为公司从二级市场回购的A股普通股股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639042306","title":"每周股票复盘：亚虹医药（688176）2025年股东会通过利润分配等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2639042306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639042306?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:57","pubTimestamp":1780171028,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，亚虹医药报收于11.38元，较上周的12.39元下跌8.15%。北京市嘉源律师事务所对江苏亚虹医药科技股份有限公司2025年年度股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序及表决结果进行了见证，并出具法律意见书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638686040","title":"亚虹医药（688176）披露2025年年度股东会法律意见书，5月27日股价下跌2.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638686040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638686040?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:19","pubTimestamp":1779891555,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘，亚虹医药报收于11.63元，较前一交易日下跌2.43%，最新总市值为66.43亿元。该股当日开盘11.98元，最高11.98元，最低11.59元，成交额达8678.65万元，换手率为1.7%。公告显示，北京市嘉源律师事务所对该公司2025年年度股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序及表决结果进行了见证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700045984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637376264","title":"每周股票复盘：亚虹医药（688176）核心产品获批推进商业化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2637376264","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637376264?lang=zh_cn&edition=full","pubTime":"2026-05-24 05:17","pubTimestamp":1779571032,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，亚虹医药报收于12.39元，较上周的12.51元下跌0.96%。本周，亚虹医药5月21日盘中最高价报13.0元。核心产品希维她获批上市，推进商业化布局。江苏亚虹医药科技股份有限公司董事会于近日收到证券事务代表季德先生递交的书面辞职报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637489593","title":"亚虹医药（688176）披露证券事务代表辞职公告，5月22日股价上涨0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637489593","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637489593?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:44","pubTimestamp":1779461057,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，亚虹医药报收于12.39元，较前一交易日上涨0.32%，最新总市值为70.77亿元。公告显示，公司董事会于近日收到证券事务代表季德先生递交的书面辞职报告。季德先生因个人原因申请辞去公司证券事务代表职务，辞职后不再担任公司任何职务。辞职报告自送达公司董事会之日起生效，其辞职不会影响公司相关工作的正常开展。公司将根据相关规定尽快聘任符合任职资格的人员担任证券事务代表。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200045531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636825356","title":"亚虹医药（688176）披露2025年年度股东会会议资料，5月20日股价下跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636825356","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636825356?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:31","pubTimestamp":1779287477,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，亚虹医药报收于12.6元，较前一交易日下跌0.32%，最新总市值为71.97亿元。该股当日开盘12.65元，最高12.9元，最低12.52元，成交额达1.22亿元，换手率为2.21%。近日，江苏亚虹医药科技股份有限公司发布2025年年度股东会会议资料。公司2025年度未盈利，拟不进行利润分配。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636062486","title":"每周股票复盘：亚虹医药（688176）希维她商业化推进及海外临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2636062486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636062486?lang=zh_cn&edition=full","pubTime":"2026-05-17 04:47","pubTimestamp":1778964429,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，亚虹医药报收于12.51元，较上周的12.98元下跌3.62%。本周，亚虹医药5月11日盘中最高价报13.3元。本周关注点来自机构调研要点：希维她?已获批上市，商业化准备工作已启动，生产和进口相关工作正积极推进。上市许可申请已获欧洲药品管理局受理，正寻求海外商业化合作。公司3月3日即已获批，3月24日即已与上药科园贸易签署分销协议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634306239","title":"股市必读：亚虹医药（688176）5月11日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2634306239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634306239?lang=zh_cn&edition=full","pubTime":"2026-05-12 01:28","pubTimestamp":1778520489,"startTime":"0","endTime":"0","summary":"截至2026年5月11日收盘，亚虹医药报收于13.17元，上涨1.46%，换手率3.09%，成交量13.48万手，成交额1.75亿元。机构调研要点5月11日举行业绩说明会，主要内容如下：公司介绍了企业情况、主要业务进展及未来发展规划。海克威方面，合作伙伴R.WOLF的蓝光膀胱镜系统SYSTEMBLUE已获NMP批准上市，诊疗方案具备临床落地基础。后续进展公司将依规履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200001395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284926","title":"亚虹医药：5月11日召开业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2634284926?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:05","pubTimestamp":1778504712,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月11日亚虹医药发布公告称公司于2026年5月11日召开业绩说明会。公司3月3日即已获批，3月24日即已与上药科园贸易签署分销协议。亚虹医药2026年一季报显示，一季度公司主营收入7108.59万元，同比上升16.34%；归母净利润-1.12亿元，同比下降34.56%；扣非净利润-1.16亿元，同比下降30.06%；负债率27.26%，投资收益131.64万元，财务费用310.64万元，毛利率72.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100034096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787724281945,"stockEarnings":[{"period":"1week","weight":-0.0866},{"period":"1month","weight":-0.0604},{"period":"3month","weight":0.0163},{"period":"6month","weight":-0.0092},{"period":"1year","weight":-0.0649},{"period":"ytd","weight":0.0269}],"compareEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0197},{"period":"3month","weight":-0.0499},{"period":"6month","weight":-0.062},{"period":"1year","weight":0.0015},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"26290人(较上一季度增加9.18%)","perCapita":"21764股","listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","registeredCapital":"57219万元","survey":" 江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域专科创新药的研发、生产和销售。公司的主要产品是APL-1702(希维她)、APL-2302、APL-2501、AT-018、AT-021、APL-1706(海克威)、APLD-2304、APL-1202、APL-2401、APL-1202、APL-1401、APL-2301。","listedPrice":22.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药-U(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药-U(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药-U,688176,亚虹医药-U股票,亚虹医药-U股票老虎,亚虹医药-U股票老虎国际,亚虹医药-U行情,亚虹医药-U股票行情,亚虹医药-U股价,亚虹医药-U股市,亚虹医药-U股票价格,亚虹医药-U股票交易,亚虹医药-U股票购买,亚虹医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药-U(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药-U(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}